Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

This study tests whether adding nintedanib — a drug that targets tumor blood vessel growth — to a standard targeted lung cancer drug (EGFR inhibitor) can help patients whose advanced non-small cell lung cancer has stopped responding to first-line EGFR therapy. **You may be eligible if...** - You are between 20 and 70 years old - You have advanced non-small cell lung cancer (stage III or IV) with an EGFR mutation - Your cancer has stopped responding to a first-generation EGFR drug (gefitinib, erlotinib, afatinib, or osimertinib) - Your lung, liver, kidney, and bone marrow function are adequate **You may NOT be eligible if...** - You have received more than one prior EGFR therapy - You have serious liver, kidney, or heart problems - You are pregnant or breastfeeding - You have uncontrolled brain metastases Talk to your doctor to see if this trial is right for you.